MTOR and pancreatic neuroendocrine tumor: Recently, the mTOR inhibitor, Everolimus, and the multi-target antiangiogenetic agent, Sunitinib, have been shown to be effective in prolonging progression-free survival (PFS) in advanced progressive pancreatic endocrine tumors (PETs), and thus have been approved by the FDA for treatment of this disease [14].